Advertisement

Diabetology International

, Volume 7, Issue 1, pp 89–94 | Cite as

A case of glucocorticoid-induced diabetes in which the efficacy between sitagliptin and metformin was compared

  • Chisaki Ishibashi
  • Tetsuyuki Yasuda
  • Taka-aki Matsuoka
  • Koichi Hirai
  • Fumie Sakamoto
  • Tetsuhiro Kitamura
  • Junji Kozawa
  • Michio Otsuki
  • Tohru Funahashi
  • Akihisa Imagawa
  • Hideaki KanetoEmail author
  • Iichiro Shimomura
Case Report

Abstract

To date, promising strategies for treating glucocorticoid (GC)-induced diabetes with antidiabetic drugs have not been established. We herein report the case of a woman with GC-induced diabetes in which we compared the efficacy of two kinds of orally administered antidiabetic drugs sitagliptin and metformin by continuous glucose monitoring (CGM) and meal-challenge test (MCT). As a result, CGM showed that daily fluctuation of blood glucose levels was reduced during administration of metformin but not during administration of sitagliptin. On the other hand, MCT showed that administration of metformin reduced plasma glucose levels accompanied by the decrease of plasma insulin levels and the increase of plasma glucagon levels, whereas administration of sitagliptin had little effects on these parameters. This case is the first report to compare the efficacy between sitagliptin and metformin in glucose homeostasis by CGM and MCT in a patient with GC-induced diabetes.

Keywords

Glucocorticoid Diabetes Sitagliptin Metformin Meal-challenge test 

Notes

Conflict of interests

None.

References

  1. 1.
    Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011;163:29–43.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Larsson H, Ahren B. Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia. 1999;42:936–43.CrossRefPubMedGoogle Scholar
  3. 3.
    Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101.CrossRefPubMedGoogle Scholar
  5. 5.
    Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17:717–20.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, Dall’omo AM, Imbimbo B. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest. 1983;72:1814–20.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30:96–102.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Baldwin D Jr, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation. 2004;77:1009–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant. 2004;4:2135–8.CrossRefPubMedGoogle Scholar
  12. 12.
    van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34:412–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Matsuo K, Nambu T, Matsuda Y, Kanai Y, Yonemitsu S, Muro S, Oki S. Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy. Intern Med. 2013;52:89–95.CrossRefPubMedGoogle Scholar
  14. 14.
    Kwon S, Hermayer KL. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013;345:274–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.CrossRefPubMedGoogle Scholar
  16. 16.
    Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010;95:3309–17.CrossRefPubMedGoogle Scholar
  17. 17.
    Jensen DH, Aaboe K, Henriksen JE, Vølund A, Holst JJ, Madsbad S, Krarup T. Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Diabetologia. 2012;55:1406–16.CrossRefPubMedGoogle Scholar
  18. 18.
    Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K. Arjona Ferreira JC, Amatruda J. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57:383–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56:1898–906.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494:256–60.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Boulé NG, Robert C, Bell GJ, Johnson ST, Bell RC, Lewanczuk RZ, Gabr RQ, Brocks DR. Metformin and exercise in type 2 diabetes: examining treatment modality interactions. Diabetes Care. 2011;34:1469–74.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japan Diabetes Society 2015

Authors and Affiliations

  • Chisaki Ishibashi
    • 1
  • Tetsuyuki Yasuda
    • 1
  • Taka-aki Matsuoka
    • 1
  • Koichi Hirai
    • 1
  • Fumie Sakamoto
    • 1
  • Tetsuhiro Kitamura
    • 1
  • Junji Kozawa
    • 1
  • Michio Otsuki
    • 1
  • Tohru Funahashi
    • 1
  • Akihisa Imagawa
    • 1
  • Hideaki Kaneto
    • 2
    Email author
  • Iichiro Shimomura
    • 1
  1. 1.Department of Metabolic Medicine, Graduate School of MedicineOsaka UniversityOsakaJapan
  2. 2.Department of Diabetes, Endocrinology and MetabolismKawasaki Medical SchoolOkayamaJapan

Personalised recommendations